Figure 3.

Gastric cancer is a target for MSLN-targeted RITs. (A) Four different gastric cancer cell lines were assessed for surface expression of MSLN as described in Figure 3A. Traces are representative runs from at least duplicate experiments. (B) MKN28 or MKN45 were treated with the indicated concentrations of SS1P or RG7787 and incubated for 72 hours before assessment of cell growth inhibition by WST-8 assay. Viability for vehicle-treated cells was normalized to 1.0, and that for cycloheximide (a positive control which reliably produces nearly 100% cell kill) was normalized to 0. Each data point represents measurements of three treated wells. (C) Female nude mice were inoculated subcutaneously with MKN28 cells at time 0. Intravenous treatment with RG7787 (2.5 mg/kg) or vehicle was given on days 5, 7 and 9. Each data point represents average of mean tumor volume for n = 10 animals treated with RG7787 or n = 5 vehicle treated animals. Arrows indicate the days that treatment was administered. There is a statistically significant difference between the two group beginning on day 7. Results shown are representative of more than three similar experiments.